US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,408.31

+29.532.14%

Number of Gainers:16

Number of Losers:3

Number of Flat:- -

PE:- -

High:1,416.55

Open:1,393.57

Low:1,391.71

Close:1,378.72

Loading ...

BUZZ-Leerink Partners raises PT on Gilead, citing HIV treatments prospects

NanoViricides: Design of Adaptive Clinical Trial Protocol for Treatment of Mpox Virus Clade Ia and Ib Infections and Disease Is Nearly Complete

THOMSON REUTERS

NanoViricides Inc. Nears Completion of Phase II Clinical Trial Design for Novel MPox Treatment NV-387

WHO recommends Gilead's twice-yearly injection for HIV prevention

BRIEF-World Health Organization Recommends Injectable Lenacapavir For HIV Prevention

Who Recommends Injectable Lenacapavir for Hiv Prevention

THOMSON REUTERS

World Health Organization: Recommends Public Health Approach to Hiv Testing Using Hiv Rapid Tests to Support Delivery of Long-Acting Injectable Prep

THOMSON REUTERS

Moderna (NasdaqGS:MRNA) Added to Russell Midcap Indexes

Simply Wall St.

3 Dividend Growth Stocks to Buy and Hold

Fielmann (0MG1) Gets a Buy from Kepler Capital

Just How Bad Is the Art Market's Case of the Blues? -- Barrons.com

Late-Trading Activity (4 p.m. - 6 p.m. Eastern Time)

Gilead estimates Q2 acquired IPR&D expenses of $61M

Co-Diagnostics Inc. Plans Reverse Stock Split to Regain NASDAQ Compliance

Pfizer’s ABRYSVO Vaccine Study: A Potential Game-Changer for Infant RSV Protection

Pfizer’s Study on Rimegepant and Pregnancy: What Investors Need to Know

Pfizer’s New Study on COVID-19 Vaccine Effectiveness: What Investors Need to Know

Pfizer’s Latest Study on HER2-positive Breast Cancer Treatment: Key Insights for Investors

GSK’s Innovative Flu/COVID-19 Combo Vaccine Study Completes: Market Implications

BioNTech’s Promising Trial: BNT113 and Pembrolizumab in Head and Neck Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4568/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1408.2572,"timestamp":1752688604664,"preClose":1378.7249,"halted":0,"volume":54580645,"delay":0,"changeRate":0.02142,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":29.532349,"latestTime":"07-16 13:56:44 EDT","open":1393.5732,"high":1416.5477,"low":1391.7104,"amount":4069096751.48618,"amplitude":0.018015,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1752696000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.703999,"peRate":22.02632,"turnoverRate":0.003565,"increases":16,"decrements":3,"flats":0,"marketCap":1161546494344.25,"floatMarketCap":1140470139380.75},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1416.5477,"amplitude":0.018015,"preClose":1378.7249,"low":1391.7104,"pbRate":"3.703999","latestPrice":1408.3119,"volume":54588193,"delay":0,"open":1393.5732,"prevYearClose":1274.8187,"prevWeekClose":1397.679,"prevMonthClose":1377.5769,"prevQuarterClose":1377.5769,"fiveDayClose":1401.8469,"twentyDayClose":1394.9728,"sixtyDayClose":1341.7848,"secType":"PLATE","market":"US","turnoverRate":0.003566,"peRate":22.02632,"marketCap":1161408931976.25,"floatMarketCap":1140332700208.75,"timestamp":1752688606110,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":16,"down":3,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2551690747","title":"BUZZ-Leerink Partners raises PT on Gilead, citing HIV treatments prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2551690747","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551690747?lang=en_us&edition=fundamental","pubTime":"2025-07-14 18:38","pubTimestamp":1752489536,"startTime":"0","endTime":"0","summary":"BUZZ-Leerink Partners raises PT on Gilead, citing HIV treatments prospects** Brokerage Leerink Partners raises PT on drugmaker Gilead Sciences GILD.O to $114 from $105 ** Brokerage says it does not anticipate any \"major top- or bottom-line surprises\" in GILD's earnings, ahead of its Q2 results likely to be reported in early August** Maintains \"outperform\" rating** The new price target represents a 3.97% upside to the stock's last close** Aside from earnings, brokerage says \"the central focus will be on two recent HIV PrEP and treatment pipeline developments\" ** Brokerage says GILD's recently approved twice-yearly injectable HIV PrEP, Yeztugo, can quickly and widely become available, considering its lower price compared to its once-daily PrEP drug, Descovy, and its efficacy even though unclear guidelines after U.S. top court ruling on preventative coverage and CMS ** Twenty of 30 brokerages rate the stock \"buy\" or higher, 10 \"hold\"; their median PT is $118.50 - data compiled by LSEG** U","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nL4N3TB0TF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU1674673691.USD","LU1571399168.USD","LU2468319806.SGD","BK4139","IE0002270589.USD","IE00BKVL7J92.USD","LU1674673428.USD","LU0234570918.USD","SG9999015952.SGD","BK4532","LU0058720904.USD","IE00BSNM7G36.USD","BK4550","BK4583","IE00B19Z3581.USD","BK4568","LU0109394709.USD","IE00B3T34201.USD","LU2089984988.USD","LU1585245621.USD","LU1066053197.SGD","IE00BZ1G4Q59.USD","SG9999015978.USD","LU1839511570.USD","LU2087621335.USD","LU0889565916.HKD","IE00B7SZLL34.SGD","SG9999015945.SGD","BK4588","LU0289739699.SGD","LU1430594728.SGD","LU1778281490.HKD","BK4566","LU1066051498.USD","GILD","LU2324357040.USD","SG9999015986.USD","LU0320765992.SGD","BK4578","BK4585","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2551907480","title":"NanoViricides: Design of Adaptive Clinical Trial Protocol for Treatment of Mpox Virus Clade Ia and Ib Infections and Disease Is Nearly Complete","url":"https://stock-news.laohu8.com/highlight/detail?id=2551907480","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551907480?lang=en_us&edition=fundamental","pubTime":"2025-07-14 18:32","pubTimestamp":1752489168,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nFWN3T905H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4568","NNVC"],"gpt_icon":0},{"id":"2551907464","title":"NanoViricides Inc. Nears Completion of Phase II Clinical Trial Design for Novel MPox Treatment NV-387","url":"https://stock-news.laohu8.com/highlight/detail?id=2551907464","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551907464?lang=en_us&edition=fundamental","pubTime":"2025-07-14 18:30","pubTimestamp":1752489033,"startTime":"0","endTime":"0","summary":"NanoViricides Inc., a publicly traded company focused on developing broad-spectrum antivirals, has announced that the design of its adaptive clinical trial protocol for treating MPox Virus Clade Ia and Ib infections with the novel drug NV-387 is nearing completion. The trial aims to gather data on safe and effective dosing regimens, the safety and tolerability of the drug, and its antiviral effectiveness. The adaptive, randomized, standard of care controlled trial will enroll approximately 80 patients and proceed in two parts. In the Phase IIa part, NV-387 will be compared with the standard of care over an initial six-day dosing period, with potential for extension based on patient outcomes. Currently, no drug is approved as effective for treating MPox. If NV-387 proves effective, it would be the first drug to demonstrate effectiveness against an orthopoxvirus in human clinical trials. Results of the trial are expected to provide crucial insights into the drug's safety and efficacy.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL6lCy3f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NNVC","BK4568","BK4139"],"gpt_icon":0},{"id":"2551909203","title":"WHO recommends Gilead's twice-yearly injection for HIV prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2551909203","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551909203?lang=en_us&edition=fundamental","pubTime":"2025-07-14 17:10","pubTimestamp":1752484246,"startTime":"0","endTime":"0","summary":"WHO recommends Gilead's twice-yearly injection for HIV preventionJuly 14  - The World Health Organization on Monday recommended Gilead's  GILD.O lenacapavir, a twice-yearly injection, for preventing HIV infection.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nL4N3TB0O6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015945.SGD","BK4578","IE00B7SZLL34.SGD","LU1585245621.USD","BK4550","LU2087621335.USD","SG9999015952.SGD","LU1430594728.SGD","LU2324357040.USD","LU1066051498.USD","LU0058720904.USD","LU1674673691.USD","LU0234570918.USD","LU1571399168.USD","SG9999015978.USD","BK4566","LU0109394709.USD","LU1778281490.HKD","BK4583","LU1674673428.USD","LU2089984988.USD","LU0289739699.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU1066053197.SGD","BK4588","BK4139","BK4585","IE00BKVL7J92.USD","LU1839511570.USD","IE0002270589.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","LU0823416689.USD","SG9999015986.USD","BK4532","LU2468319806.SGD","IE00B3T34201.USD","LU0320765992.SGD","BK4568","GILD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2551172909","title":"BRIEF-World Health Organization Recommends Injectable Lenacapavir For HIV Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2551172909","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551172909?lang=en_us&edition=fundamental","pubTime":"2025-07-14 17:03","pubTimestamp":1752483838,"startTime":"0","endTime":"0","summary":"BRIEF-World Health Organization Recommends Injectable Lenacapavir For HIV PreventionJuly 14  - World Health Organization:WHO RECOMMENDS INJECTABLE LENACAPAVIR FOR HIV PREVENTIONWORLD HEALTH ORGANIZATION: RECOMMENDS PUBLIC HEALTH APPROACH TO HIV TESTING USING HIV RAPID TESTS TO SUPPORT DELIVERY OF LONG-ACTING INJECTABLE PREPFurther company coverage: GILD.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nFWN3TA01I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IE00B19Z3581.USD","LU0823416689.USD","BK4550","LU2468319806.SGD","IE00B19Z3B42.SGD","LU1571399168.USD","BK4578","LU1778281490.HKD","IE00B7SZLL34.SGD","LU0320765992.SGD","SG9999015945.SGD","BK4139","BK4568","LU1585245621.USD","LU2324357040.USD","SG9999015978.USD","BK4532","SG9999015952.SGD","IE00B3T34201.USD","LU0058720904.USD","LU0289739699.SGD","LU1674673691.USD","LU0889565916.HKD","LU1674673428.USD","BK4585","LU0109394709.USD","LU1066051498.USD","BK4583","GILD","LU1430594728.SGD","LU1066053197.SGD","LU1839511570.USD","IE00BKVL7J92.USD","LU2089984988.USD","IE00BZ1G4Q59.USD","SG9999015986.USD","LU0234570918.USD","IE0002270589.USD","IE00BSNM7G36.USD","LU2087621335.USD","BK4588"],"gpt_icon":0},{"id":"2551909364","title":"Who Recommends Injectable Lenacapavir for Hiv Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2551909364","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551909364?lang=en_us&edition=fundamental","pubTime":"2025-07-14 17:00","pubTimestamp":1752483653,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nFWN3TA01I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B3T34201.USD","BK4139","LU2324357040.USD","IE00BKVL7J92.USD","LU1674673691.USD","LU2089984988.USD","LU0823416689.USD","BK4566","LU2087621335.USD","LU0109394709.USD","LU1066051498.USD","IE00BZ1G4Q59.USD","LU2468319806.SGD","LU0889565916.HKD","LU0234570918.USD","LU1674673428.USD","SG9999015945.SGD","BK4568","IE00BSNM7G36.USD","SG9999015978.USD","LU0320765992.SGD","GILD","IE00B19Z3B42.SGD","BK4578","SG9999015986.USD","BK4585","LU1839511570.USD","BK4583","LU1778281490.HKD","LU0058720904.USD","SG9999015952.SGD","LU1430594728.SGD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","LU1585245621.USD","LU1571399168.USD","LU0289739699.SGD","LU1066053197.SGD","BK4550","BK4532","BK4588","IE0002270589.USD"],"gpt_icon":0},{"id":"2551096869","title":"World Health Organization: Recommends Public Health Approach to Hiv Testing Using Hiv Rapid Tests to Support Delivery of Long-Acting Injectable Prep","url":"https://stock-news.laohu8.com/highlight/detail?id=2551096869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551096869?lang=en_us&edition=fundamental","pubTime":"2025-07-14 17:00","pubTimestamp":1752483653,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nFWN3TA01I:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU1066053197.SGD","BK4550","LU2324357040.USD","LU1066051498.USD","SG9999015952.SGD","LU0109394709.USD","LU1778281490.HKD","GILD","LU0289739699.SGD","BK4532","LU2089984988.USD","SG9999015945.SGD","BK4588","IE00B19Z3581.USD","LU1674673428.USD","IE00B7SZLL34.SGD","LU1674673691.USD","BK4578","LU0889565916.HKD","LU0058720904.USD","LU1571399168.USD","BK4585","LU0234570918.USD","LU0823416689.USD","LU0320765992.SGD","LU2468319806.SGD","LU1839511570.USD","IE00B19Z3B42.SGD","LU2087621335.USD","LU1585245621.USD","IE00B3T34201.USD","SG9999015978.USD","BK4568","BK4566","LU1430594728.SGD","IE00BKVL7J92.USD","IE0002270589.USD","IE00BSNM7G36.USD","SG9999015986.USD","IE00BZ1G4Q59.USD","BK4583"],"gpt_icon":0},{"id":"2551911206","title":"Moderna (NasdaqGS:MRNA) Added to Russell Midcap Indexes","url":"https://stock-news.laohu8.com/highlight/detail?id=2551911206","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551911206?lang=en_us&edition=fundamental","pubTime":"2025-07-13 01:24","pubTimestamp":1752341065,"startTime":"0","endTime":"0","summary":"Moderna (NasdaqGS:MRNA) recently experienced significant index changes, with the company being added to the Russell Midcap and Midcap Value indexes, while being dropped from several others. Over the last quarter, its share price recorded a notable rise of 28%, against a backdrop of a flat broader market. This performance could be partly influenced by these index adjustments, as they often affect institutional investment decisions. Additionally, developments such as expanded collaborations and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/moderna-nasdaqgsmrna-added-to-russell-midcap-indexes","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4568","BK4551","BK4534","BK4532","BK4548","BK4585","BK4139","BK4588","BK4533","MRNA","BK4501"],"gpt_icon":1},{"id":"2550976369","title":"3 Dividend Growth Stocks to Buy and Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2550976369","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550976369?lang=en_us&edition=fundamental","pubTime":"2025-07-12 18:40","pubTimestamp":1752316800,"startTime":"0","endTime":"0","summary":"Abbott Laboratories is a dividend growth machine that's known for consistency.AbbVie's dividend has more than quadrupled since 2013.Eli Lilly offers dividend growth and, more importantly, tremendous share price growth.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/07/12/3-dividend-growth-stocks-to-buy-and-hold/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4533","ABT","SGXZ23171101.USD","BK4566","LU1057294990.SGD","IE00B2B36J28.USD","SG9999004303.SGD","LU2089984988.USD","LU2112291526.USD","BK4504","BK4585","LU2237957811.SGD","BK4581","LU1023059063.AUD","BK4588","IE0009355771.USD","LU1721429402.USD","LU1989763690.USD","BK4082","IE00B4R5TH58.HKD","LU0266013472.USD","LU1061106388.HKD","LU1721429741.USD","LU2237957902.USD","LU0234572021.USD","LU0122379950.USD","IE00BJJMRZ35.SGD","BK4592","SG9999002224.SGD","IE00BJT1NW94.SGD","SG9999002232.USD","LU0868494617.USD","IE0002141913.USD","LU0170899867.USD","LU2133065610.SGD","LU2468319806.SGD","IE00BFTCPJ56.SGD","LU1691799644.USD","LU1914381329.SGD","LU1989763427.SGD","BK4568"],"gpt_icon":0},{"id":"2550236998","title":"Fielmann (0MG1) Gets a Buy from Kepler Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2550236998","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550236998?lang=en_us&edition=fundamental","pubTime":"2025-07-12 09:35","pubTimestamp":1752284116,"startTime":"0","endTime":"0","summary":"Kepler Capital analyst Craig Abbott maintained a Buy rating on Fielmann on July 10 and set a price target of €60.00. The company’s shares closed la...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/fielmann-0mg1-gets-a-buy-from-kepler-capital-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/fielmann-0mg1-gets-a-buy-from-kepler-capital-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1914381329.SGD","IE0009355771.USD","SG9999002232.USD","LU1721429741.USD","BK4592","IE0002141913.USD","LU2112291526.USD","IE00BFTCPJ56.SGD","LU0234572021.USD","LU1989763427.SGD","SG9999002224.SGD","LU1691799644.USD","IE00B2B36J28.USD","LU1721429402.USD","LU1057294990.SGD","LU0266013472.USD","LU1989763690.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0122379950.USD","BK4581","SG9999004303.SGD","BK4504","BK4566","BK4533","BK4585","LU2237957811.SGD","LU0170899867.USD","ABT","IE00B4R5TH58.HKD","SGXZ23171101.USD","LU1023059063.AUD","BK4588","LU2133065610.SGD","LU1061106388.HKD","BK4082","LU2089984988.USD","LU0868494617.USD","BK4568","LU2468319806.SGD","LU2237957902.USD"],"gpt_icon":0},{"id":"2550962765","title":"Just How Bad Is the Art Market's Case of the Blues? -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2550962765","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550962765?lang=en_us&edition=fundamental","pubTime":"2025-07-12 07:10","pubTimestamp":1752275400,"startTime":"0","endTime":"0","summary":"The art market has the blues. A recent paper from finance scholars Jianping Mei and Michael Moses sums it up: \"As Bad as It Gets With No Green Shoots in Sight.\" In fact, says Moses, results have been \"consistently poor\" for the past six auction seasons. \"There's never been a time this century when returns have been this bad for this long,\" he says.While first-half New York sales rose 1.2% at the three big auction houses -- Christie's, Sotheby's, and Phillips -- global sales fell 6.2%, notes data and analysis firm ArtTactic. Growth, inflation, and geopolitical concerns \"are weighing on confidence and creating a more cautious investment climate,\" writes ArtTactic CEO Anders Petterson.\"If you believe in mean reversion, which we do, this might not be a bad buying opportunity,\" says Moses.Chinese online fast-fashion retailer Shein applied to go public in Hong Kong after attempting to list in London...AI cloud provider CoreWeave agreed to buy data-center operator Core Scientific for $9 billi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4591","LU1211504680.USD","LU1989763690.USD","LU2347655156.SGD","BK4543","LU0912757837.SGD","LU0878005551.USD","IE00B775H168.HKD","LU2237957811.SGD","BK4605","KHC","LU2211814178.USD","AXP","LU0868494708.USD","LU2461242641.AUD","LU0795875169.SGD","LU2249611893.SGD","LU0225283273.USD","BK4568","LU0006306889.USD","LU0234572021.USD","LU0648001328.SGD","LU0980610538.SGD","LU2112291526.USD","LU2361044865.SGD","IE00B2B36J28.USD","LU1989772923.USD","03145","LU2552382215.SGD","ABT","IE00BQXX3C00.GBP","LU1674673691.USD","LU0267386448.USD","LU2360032135.SGD","LU0792757196.USD","LU0306806265.USD","IE0004445239.USD","LU1691799644.USD","IE00B3M56506.USD","SGXZ81514606.USD","LU0353189680.USD","IE00BKVL7J92.USD","LU1989763427.SGD","LU2111349929.HKD","LU1023057109.AUD","LU1363072403.SGD","LU1868837565.USD","BK4559","BK4588"],"gpt_icon":1},{"id":"2550964048","title":"Late-Trading Activity (4 p.m. - 6 p.m. Eastern Time)","url":"https://stock-news.laohu8.com/highlight/detail?id=2550964048","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550964048?lang=en_us&edition=fundamental","pubTime":"2025-07-12 06:07","pubTimestamp":1752271620,"startTime":"0","endTime":"0","summary":"ISSUE                   EXCH   VOL        LAST     NET CHG       % CHG. SPDR S&P 500                 4,015.7      623.21       —0.41        —0.1","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0979878070.USD","NA","BK4543","IE00BBT3K403.USD","LU1244550494.USD","LU1244550577.SGD","IE00B19Z9Z06.USD","LU1894683264.USD","BK4548","LU0058720904.USD","BK4504","IE00B19Z9P08.USD","LU1046421795.USD","LU1880383366.USD","PFE","BK4161","LU0348814723.USD","IE00BLSP4239.USD","BK4007","LU1688375341.USD","LU0320765489.SGD","EML","LU1242518931.SGD","LU1515016050.SGD","BK4614","INTC","LU0128525929.USD","LU0306807586.USD","BK4575","LU1769817096.USD","SG9999002224.SGD","SG9999002232.USD","CMCSA","BK4534","LU1059921491.USD","BK4592","LU0029864427.USD","LU1008478684.HKD","LU1150488218.USD","BK4568","BK4512","BK4599","SG9999013999.USD","ALBmain","LU1235294995.USD","BK4531","LU0234572021.USD","BK4565"],"gpt_icon":1},{"id":"2550577964","title":"Gilead estimates Q2 acquired IPR&D expenses of $61M","url":"https://stock-news.laohu8.com/highlight/detail?id=2550577964","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550577964?lang=en_us&edition=fundamental","pubTime":"2025-07-12 05:15","pubTimestamp":1752268510,"startTime":"0","endTime":"0","summary":"For the second quarter of 2025, Gilead (GILD) currently expects $61M in acquired IPR&D expenses, representing a charge of roughly 4c to both GAAP a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-estimates-q2-acquired-iprd-expenses-of-61m-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-estimates-q2-acquired-iprd-expenses-of-61m-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1571399168.USD","BK4139","LU0109394709.USD","IE00B19Z3B42.SGD","IE0002270589.USD","IE00BKVL7J92.USD","BK4566","IE00B7SZLL34.SGD","LU0889565916.HKD","IE00BSNM7G36.USD","LU2087621335.USD","BK4578","BK4585","BK4532","GILD","IE00B19Z3581.USD","LU1839511570.USD","LU0320765992.SGD","LU0234570918.USD","LU1674673428.USD","SG9999015986.USD","BK4550","LU2468319806.SGD","SG9999015978.USD","LU0823416689.USD","IE00BZ1G4Q59.USD","LU0289739699.SGD","LU1066051498.USD","LU2089984988.USD","BK4583","LU1066053197.SGD","LU2324357040.USD","SG9999015952.SGD","IE00B3T34201.USD","BK4588","LU1430594728.SGD","LU1674673691.USD","BK4568","LU1778281490.HKD","SG9999015945.SGD","LU0058720904.USD","LU1585245621.USD"],"gpt_icon":0},{"id":"2550969481","title":"Co-Diagnostics Inc. Plans Reverse Stock Split to Regain NASDAQ Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2550969481","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550969481?lang=en_us&edition=fundamental","pubTime":"2025-07-12 04:16","pubTimestamp":1752264980,"startTime":"0","endTime":"0","summary":"Co-Diagnostics Inc. has announced its intention to address its non-compliance with NASDAQ's $1.00 minimum bid requirement by considering a reverse stock split. The company has been granted an additional 180-day grace period, until January 5, 2026, to meet the requirement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250711:nNDL7mVFDf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ","BK4082","IE00B64PRP62.GBP","BK4568","CODX","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4588","LU2095319765.USD","BK4585","LU2210150020.SGD","BK4112"],"gpt_icon":0},{"id":"2550646968","title":"Pfizer’s ABRYSVO Vaccine Study: A Potential Game-Changer for Infant RSV Protection","url":"https://stock-news.laohu8.com/highlight/detail?id=2550646968","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550646968?lang=en_us&edition=fundamental","pubTime":"2025-07-12 00:29","pubTimestamp":1752251383,"startTime":"0","endTime":"0","summary":"Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Study Overview: Pfizer Inc. is conducting a study titled Real World Impact...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pfizers-abrysvo-vaccine-study-a-potential-game-changer-for-infant-rsv-protection?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pfizers-abrysvo-vaccine-study-a-potential-game-changer-for-infant-rsv-protection?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SG9999001176.USD","LU0306806265.USD","BK4550","LU0225284248.USD","BK4533","LU0868494617.USD","BK4568","SG9999002232.USD","BK4007","SG9999003800.SGD","LU0058720904.USD","PFE","BK4534","LU0170899867.USD","LU1894683264.USD","BK4588","LU0456855351.SGD","SG9999002224.SGD","LU0289739699.SGD","LU0122379950.USD","BK4585","BK4592","LU1023059063.AUD","BK4599","BK4581","LU1894683348.USD","LU0234572021.USD","SG9999013999.USD","IE00B19Z3B42.SGD","LU0985481810.HKD","IE0002270589.USD","LU1057294990.SGD","LU1883839398.USD","SG9999001176.SGD","IE00BLSP4239.USD","IE00BBT3K403.USD","LU0321505868.SGD","IE00B19Z3581.USD","LU1066053197.SGD","LU0225771236.USD","LU0321505439.SGD","LU0306807586.USD","SG9999011175.SGD","SGXZ57979304.SGD","IE000M9KFDE8.USD","LU1066051498.USD","IE00BLSP4452.SGD"],"gpt_icon":0},{"id":"2550968679","title":"Pfizer’s Study on Rimegepant and Pregnancy: What Investors Need to Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2550968679","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550968679?lang=en_us&edition=fundamental","pubTime":"2025-07-12 00:29","pubTimestamp":1752251374,"startTime":"0","endTime":"0","summary":"Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a study titled ‘Retrospective Cohort Study of Pr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pfizers-study-on-rimegepant-and-pregnancy-what-investors-need-to-know?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pfizers-study-on-rimegepant-and-pregnancy-what-investors-need-to-know?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4592","LU0234572021.USD","BK4211","IE00BLSP4239.USD","LU0306807586.USD","LU0868494617.USD","BK4581","LU1066051498.USD","IE00BLSP4452.SGD","SG9999001176.USD","BK4585","SG9999003800.SGD","BK4007","SG9999011175.SGD","LU0122379950.USD","LU1066053197.SGD","LU0225771236.USD","LU0306806265.USD","BK4568","LU1894683348.USD","IE00BBT3K403.USD","BK4588","SG9999013999.USD","LU1023059063.AUD","LU0058720904.USD","BK4533","LU1057294990.SGD","IE00B19Z3581.USD","SG9999001176.SGD","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","IE0002270589.USD","BK4550","LU0225284248.USD","LU0321505439.SGD","LU1883839398.USD","LU0321505868.SGD","SG9999002232.USD","ISBC","LU0985481810.HKD","PFE","LU1894683264.USD","BK4599","LU0456855351.SGD","SGXZ57979304.SGD","LU0289739699.SGD","SG9999002224.SGD","BK4534","LU0170899867.USD"],"gpt_icon":0},{"id":"2550627968","title":"Pfizer’s New Study on COVID-19 Vaccine Effectiveness: What Investors Need to Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2550627968","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550627968?lang=en_us&edition=fundamental","pubTime":"2025-07-12 00:28","pubTimestamp":1752251329,"startTime":"0","endTime":"0","summary":"Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a study titled ‘Use and Effectiveness of COVID-1...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pfizers-new-study-on-covid-19-vaccine-effectiveness-what-investors-need-to-know?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pfizers-new-study-on-covid-19-vaccine-effectiveness-what-investors-need-to-know?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE000M9KFDE8.USD","LU1066053197.SGD","LU1883839398.USD","BK4534","SG9999002224.SGD","IE00BLSP4239.USD","BK4568","BK4588","LU0225771236.USD","BK4581","LU0170899867.USD","LU0321505439.SGD","IE00BLSP4452.SGD","LU1023059063.AUD","BK4533","LU0058720904.USD","LU1894683348.USD","IE0002270589.USD","BK4592","IE00B19Z3581.USD","LU0122379950.USD","SG9999001176.SGD","SG9999002232.USD","BK4007","LU0985481810.HKD","LU1066051498.USD","BK4211","BNTX","SGXZ57979304.SGD","BK4599","LU0868494617.USD","BK4139","IE00B19Z3B42.SGD","BK4550","BK4535","BK4548","BK4585","LU1057294990.SGD","SG9999003800.SGD","SG9999013999.USD","BK4551","ISBC","LU0306807586.USD","LU0456855351.SGD","LU0225284248.USD","IE00BBT3K403.USD","SG9999001176.USD","LU0321505868.SGD","PFE","SG9999011175.SGD"],"gpt_icon":0},{"id":"2550640968","title":"Pfizer’s Latest Study on HER2-positive Breast Cancer Treatment: Key Insights for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2550640968","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550640968?lang=en_us&edition=fundamental","pubTime":"2025-07-12 00:26","pubTimestamp":1752251182,"startTime":"0","endTime":"0","summary":"Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a study titled ‘Real-world Clinical Outcomes of ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pfizers-latest-study-on-her2-positive-breast-cancer-treatment-key-insights-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pfizers-latest-study-on-her2-positive-breast-cancer-treatment-key-insights-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4007","LU0321505868.SGD","SG9999001176.USD","LU0289739699.SGD","BK4550","ISBC","LU1066053197.SGD","PFE","SG9999001176.SGD","SG9999013999.USD","BK4592","SGXZ57979304.SGD","LU1023059063.AUD","BK4534","IE00BBT3K403.USD","BK4533","LU0170899867.USD","BK4581","LU0234572021.USD","LU0456855351.SGD","SG9999002224.SGD","SG9999003800.SGD","LU1894683348.USD","LU1894683264.USD","SG9999002232.USD","IE000M9KFDE8.USD","LU1057294990.SGD","IE0002270589.USD","BK4588","BK4599","IE00B19Z3B42.SGD","LU0058720904.USD","LU0306806265.USD","LU0225284248.USD","LU1883839398.USD","LU0868494617.USD","LU0985481810.HKD","IE00BLSP4239.USD","IE00BLSP4452.SGD","LU0225771236.USD","BK4211","BK4568","LU0306807586.USD","LU0321505439.SGD","SG9999011175.SGD","LU1066051498.USD","IE00B19Z3581.USD","LU0122379950.USD"],"gpt_icon":0},{"id":"2550950741","title":"GSK’s Innovative Flu/COVID-19 Combo Vaccine Study Completes: Market Implications","url":"https://stock-news.laohu8.com/highlight/detail?id=2550950741","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550950741?lang=en_us&edition=fundamental","pubTime":"2025-07-12 00:19","pubTimestamp":1752250780,"startTime":"0","endTime":"0","summary":"GlaxoSmithKline (($GSK)), GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) has recen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gsks-innovative-flu-covid-19-combo-vaccine-study-completes-market-implications?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gsks-innovative-flu-covid-19-combo-vaccine-study-completes-market-implications?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4568","UK","BK4532","BK4233","BK4588","GSK","GSK.UK","BK4007","BK4548","BK4205","BNTX","BK4551","BK4528","LU1829250122.USD","BK4535","BK4585"],"gpt_icon":0},{"id":"2550950743","title":"BioNTech’s Promising Trial: BNT113 and Pembrolizumab in Head and Neck Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2550950743","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550950743?lang=en_us&edition=fundamental","pubTime":"2025-07-12 00:14","pubTimestamp":1752250492,"startTime":"0","endTime":"0","summary":"Biontech SE (($CC:BNTX.CUR)), Biontech Se Sponsored Adr (($BNTX)) announced an update on their ongoing clinical study. BioNTech SE is conducting a ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biontechs-promising-trial-bnt113-and-pembrolizumab-in-head-and-neck-cancer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biontechs-promising-trial-bnt113-and-pembrolizumab-in-head-and-neck-cancer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4139","BNTX","BK4568","BK4588","BK4548","BK4551","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}